iNNOVATE™: Living longer without progression, IMBRUVICA® + rituximab vs rituximab

iNNOVATE™ Study design1

iNNOVATE™ was a randomized, double-blind, placebo-controlled, phase 3 study of treatment-naïve and previously treated patients (n=150).

Superior PFS with up to 5 years of follow-up1

Primary endpoint: Progression-free survival (PFS)1-3

IMBRUVICA® (ibrutinib) + rituximab iNNOVATE™ PFS graph in Waldenström’s macroglobulinemia patients
  • Long-term data from final analysis, with overall follow-up of 63 months; median follow-up was 50 months1,3

*P value is from the stratified log-rank test.

Abbreviations

CI=confidence interval, HR=hazard ratio, NE=not evaluable, PFS=progression-free survival, WM=Waldenström’s macroglobulinemia.

References

1IMBRUVICA® (ibrutinib) Prescribing Information. 2Data on file. 3Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40(1):52-62. doi:10.1200/JCO.21.00838